Physician profile
Steven Jones
NPI 1497722599
$3,763.99
in general payments reported to CMS, 2019-2025
41 companies · $530 in 2025
The $530 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $233 · 2021: $153 · 2022: $428 · 2023: $632 · 2024: $839 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $443.55 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $415.30 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $354.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $290.00 | 2023-2025 | Veozah, Myrbetriq, Vesicare |
| Pfizer INC. | $264.87 | 2020-2025 | |
| Glaxosmithkline, LLC. | $256.12 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $254.14 | 2019-2025 | |
| Amgen INC. | $196.96 | 2019-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $148.89 | 2024-2025 | Voquezna |
| Abbvie INC. | $145.70 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.06 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $94.29 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $80.79 | 2022-2023 | |
| Exact Sciences Corporation | $66.15 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company Ltd. | $50.59 | 2022 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.